New hope for advanced tumors: first human trial of SIGX1094R begins
Disease control
Recruiting now
This early-stage study tests a new drug called SIGX1094R in about 102 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants will receive th…
Phase: PHASE1 • Sponsor: Signet Therapeutics • Aim: Disease control
Last updated May 11, 2026 20:40 UTC